Small Pharma (DMT) Stock Price, News & Analysis C$0.15 -0.01 (-6.25%) (As of 10/20/2023) Add Compare Share Share Today's RangeC$0.15▼C$0.1650-Day RangeC$0.15▼C$0.1952-Week RangeC$0.06▼C$0.22Volume1.89 million shsAverage Volume296,159 shsMarket CapitalizationC$50.37 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider Trades About Small Pharma Stock (CVE:DMT)Small Pharma Inc., a biotechnology company, focuses on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions. Its clinical program is based on N,N, dimethyltryptamine, a naturally occurring psychoactive molecule. The company's product includes SPL026, which is in clinical Phase IIa for the treatment of major depressive disorder; and SPL028, an injectable formulation of deuterated DMT, which is in Phase 1 clinical trial, as well as SPL801B, an oral dosage. Its preclinical stage programs include SPL029, an oral formulation of a tryptamine to treat depressive disorder. The company is headquartered in London, the United Kingdom. As of October 23, 2023, Small Pharma Inc. operates as a subsidiary of Cybin Inc.Read More DMT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DMT Stock News HeadlinesDecember 5, 2023 | msn.comSmall Pharma Tackles Major Depression with Potentially Game Changing Psychedelic TherapyOctober 23, 2023 | finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - DMTDecember 10, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comOctober 20, 2023 | benzinga.comSmall Pharma's Q2 2024 Financial Highlights Ahead Of Cybin Merger For Global DMT BusinessOctober 20, 2023 | finanznachrichten.deSmall Pharma Inc.: Small Pharma Reports Fiscal Second Quarter 2024 HighlightsOctober 17, 2023 | theglobeandmail.comClosing Bell: Small Pharma Inc down on Monday (DMT)October 12, 2023 | markets.businessinsider.comSmall Pharma Announces Voting Results from Annual General and Special Meeting of ShareholdersOctober 3, 2023 | theglobeandmail.comClosing Bell: Small Pharma Inc up on Monday (DMT)December 10, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comSeptember 28, 2023 | theglobeandmail.comClosing Bell: Small Pharma Inc down on Wednesday (DMT)August 28, 2023 | finance.yahoo.comCanadian Investment Regulatory Organization Trade Resumption - DMTAugust 26, 2023 | theglobeandmail.comClosing Bell: Small Pharma Inc up on Friday (DMT)August 25, 2023 | theglobeandmail.comClosing Bell: Small Pharma Inc down on Thursday (DMT)July 28, 2023 | finanznachrichten.deSmall Pharma Inc.: Small Pharma Reports Fiscal First Quarter 2024 HighlightsJuly 28, 2023 | finance.yahoo.comSmall Pharma Reports Fiscal First Quarter 2024 HighlightsJuly 5, 2023 | msn.comSmall Pharma Implements Costs Cut: New R&D Strategy And Management Team ChangeJuly 5, 2023 | finance.yahoo.comSmall Pharma Announces SPL028 R&D Strategy UpdateJuly 5, 2023 | benzinga.comSmall Pharma Announces Management Team ChangeJune 29, 2023 | benzinga.comSmall Pharma Implements Cost-Cutting Strategy To Reduce Cash Burn As Trial ProgressesJune 2, 2023 | msn.comSmall Pharma (TSX:DMT) Price Target Increased by 36.36% to 3.83May 26, 2023 | msn.comSmall Pharma's IP Portfolio Grows With Numerous Approved Patent Applications Around The WorldMay 19, 2023 | finance.yahoo.comHere's Why We're A Bit Worried About Small Pharma's (CVE:DMT) Cash Burn SituationMay 6, 2023 | theglobeandmail.comClosing Bell: Small Pharma Inc flat on Friday (DMT)May 2, 2023 | theglobeandmail.comClosing Bell: Small Pharma Inc flat on Monday (DMT)April 29, 2023 | theglobeandmail.comClosing Bell: Small Pharma Inc down on Friday (DMT)April 27, 2023 | theglobeandmail.comClosing Bell: Small Pharma Inc up on Wednesday (DMT)April 20, 2023 | theglobeandmail.comClosing Bell: Small Pharma Inc flat on Wednesday (DMT)See More Headlines Receive DMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Small Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/19/2023Today12/10/2023Next Earnings (Estimated)1/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeCVE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolCVE:DMT CUSIPN/A CIKN/A Webwww.smallpharma.co.uk Phone44 78 1212 1944FaxN/AEmployees13Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-19,310,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-116.90% Return on Assets-66.00% Debt Debt-to-Equity Ratio5.95 Current Ratio2.63 Quick Ratio6.28 Sales & Book Value Annual SalesC$-1,162.00 Price / Sales-43,343.80 Cash FlowC$0.13 per share Price / Cash Flow1.13 Book ValueC$0.03 per share Price / Book5.00Miscellaneous Outstanding Shares335,770,000Free FloatN/AMarket CapC$50.37 million OptionableNot Optionable Beta0.86 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. George TzirasCEO & Non-Independent DirectorMr. David SteelChief Financial OfficerDr. Carol RoutledgeChief Scientific & Medical OfficerMs. Marie Claire Layzell (Age 46)Chief Manufacturing & Development Officer & Director Comp: $457.93kDr. Alastair James Riddell M.D. (Age 74)M.Sc., MBChB, MFPM, MRCGP, Ph.D., Chief Operating Officer Ms. Jenny MaguireHead of Brand & CommunicationsMs. Emma HodgeHead of Intellectual PropertyMr. Richard M. Kimel HBA (Age 56)LLB, Corporate Secretary Ms. Sarah HamiltonGroup Financial ControllerMr. Jim RennieDirector of Development and Member of Scientific & Advisory BoardMore ExecutivesKey CompetitorsHelix BioPharmaTSE:HBPProMIS NeurosciencesTSE:PMNEmerald Health TherapeuticsCVE:EMHMicrobix BiosystemsTSE:MBXAntibe TherapeuticsTSE:ATEView All CompetitorsInsidersPeter David RandsSold 638,000 sharesTotal: C$43,511.60 ($0.07/share)View All Insider Transactions DMT Stock Analysis - Frequently Asked Questions Should I buy or sell Small Pharma stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Small Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DMT shares. View DMT analyst ratings or view top-rated stocks. How have DMT shares performed in 2023? Small Pharma's stock was trading at C$0.09 on January 1st, 2023. Since then, DMT shares have increased by 66.7% and is now trading at C$0.15. View the best growth stocks for 2023 here. When is Small Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, January 24th 2024. View our DMT earnings forecast. How were Small Pharma's earnings last quarter? Small Pharma Inc. (CVE:DMT) issued its quarterly earnings data on Thursday, October, 19th. The company reported ($0.01) earnings per share (EPS) for the quarter. How do I buy shares of Small Pharma? Shares of DMT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (CVE:DMT) was last updated on 12/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Small Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.